Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
South Plains Oncology Consortium
South Plains Oncology Consortium
South Plains Oncology Consortium
Children's Oncology Group
Children's Oncology Group
Canadian Cancer Trials Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group